Ma Songjiang Insider Trading Activity

Average Profitability
<0.0001%
Insider Buys Quantity
0
Insider Buys Sum
$0
Insider Sells Quantity
64
Insider Sells Sum
$1.34M

Insider Activity of Ma Songjiang

Biography of Ma Songjiang

No biography is available at this moment.

2025-05-28SaleGyre Therapeutics, Inc.
GYRE
President
558
0.0007%
$10.07$5,619-18.54%
2025-05-27SaleGyre Therapeutics, Inc.
GYRE
President
2,000
0.0023%
$10.28$20,560-24.46%
2025-05-23SaleGyre Therapeutics, Inc.
GYRE
President
182
0.0002%
$10.24$1,864-11.41%
2025-05-22SaleGyre Therapeutics, Inc.
GYRE
President
2,000
0.0022%
$10.97$21,940-31.4%
2025-05-21SaleGyre Therapeutics, Inc.
GYRE
President
2,000
0.0024%
$10.83$21,660-25.84%
2025-05-20SaleGyre Therapeutics, Inc.
GYRE
President
2,000
0.0022%
$11.25$22,500-32.46%
2025-05-19SaleGyre Therapeutics, Inc.
GYRE
President
2,000
0.0023%
$11.11$22,220-30.69%
2025-05-16SaleGyre Therapeutics, Inc.
GYRE
President
2,000
0.0023%
$11.31$22,620-32.07%
2025-05-15SaleGyre Therapeutics, Inc.
GYRE
President
2,000
0.0021%
$10.68$21,360-29.52%
2025-05-14SaleGyre Therapeutics, Inc.
GYRE
President
20
<0.0001%
$11.30$226-25.7%
2025-05-13SaleGyre Therapeutics, Inc.
GYRE
President
2,000
0.0021%
$11.37$22,740-32.78%
2025-05-12SaleGyre Therapeutics, Inc.
GYRE
President
2,000
0.0021%
$10.56$21,120-28.62%
2025-03-21SaleGyre Therapeutics, Inc.
GYRE
President
174
0.0002%
$10.00$1,740-19.41%
2025-03-20SaleGyre Therapeutics, Inc.
GYRE
President
2,000
0.0023%
$10.09$20,180-23.39%
2025-03-19SaleGyre Therapeutics, Inc.
GYRE
President
2,000
0.0023%
$10.13$20,260-23.83%
2025-03-18SaleGyre Therapeutics, Inc.
GYRE
President
242
0.0003%
$10.24$2,478-8.4%
2025-03-17SaleGyre Therapeutics, Inc.
GYRE
President
2,000
0.0023%
$12.09$24,180-36.07%
2025-03-14SaleGyre Therapeutics, Inc.
GYRE
President
2,000
0.0024%
$12.31$24,620-35.18%
2025-03-13SaleGyre Therapeutics, Inc.
GYRE
President
2,000
0.0023%
$11.80$23,600-34.36%
2025-03-12SaleGyre Therapeutics, Inc.
GYRE
President
2,000
0.0023%
$11.74$23,480-32.56%
Total: 76
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.